Acceptability of mifepristone for early pregnancy interruption.
It is the purpose of this article to review the current status of early pregnancy interruption with mifepristone (RU 486) combined with a prostaglandin analogue from the standpoint of its acceptability to women. Also discussed are the need for uniform terminology in acceptability studies, observations from clinical trials in California, France, and the United Kingdom, and comments on eventual utilization in developing countries.